retatrutide investigational drug triple hormone receptor agonist 💉 A triple-action once-weekly injection can significantly lower blood sugar and body weight in people with type 2 diabetes, a new phase 3 trial shows. is part of an emerging generation Retatrutide—A Game Changer in Obesity

In comparison, a clinical study of Wegovy showed an average weight loss of 15% of body weight after 68 weeks of treatment

You may be a good candidate for semaglutide if you are overweight or obese and at risk for weight-related conditions such as high blood pressure, type 2 diabetes, or high cholesterol

Heffernan M, Summers RJ, Thorburn A, et al

Food and Drug Administration rules

Swollen arm got 'significantly better' To properly look into any benefits, Dayan has launched the first prospective study on GLP-1s to treat lymphedema, aiming to enroll 110 patients and publish the results next year

One side of my face has already disappeared